Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Oct 7, 2015 at 2:46 PM EDT

Why Mallinckrodt Shares Could Double

ThinkstockMallinckrodt PLC (NYSE: MNK) has been making waves in the market recently related to its guidance and it has caught the…

Chris Lange | Oct 7, 2015 at 11:35 AM EDT

Aclaris Enters Market Well Below Expected Range in IPO

Aclaris Therapeutics debuted on the market in its initial public offering (IPO) on Wednesday morning.

Lee Jackson | Oct 7, 2015 at 8:40 AM EDT

Why Merrill Lynch Now Favors Large Cap Leaders in Biotech

These four top large cap biotechs are very good bets for investors looking to add high-quality companies with less volatility…

Chris Lange | Oct 6, 2015 at 10:35 AM EDT

Why Sarepta Deserves Praise for Capital Raise Despite Stock Drop

Sarepta announced a public offering of more than 3 million shares of its common stock at a price to the…

Chris Lange | Oct 5, 2015 at 1:20 PM EDT

Can ContraVir Sustain This Move in a Shaky Health Care Sector?

ContraVir Pharmaceuticals led the bulls’ charge in the market on Monday, with shares practically doubling in what was thought to…

Lee Jackson | Oct 5, 2015 at 10:20 AM EDT

3 Biotech Stocks Loved by Portfolio Managers Now

A new report from Cowen points out that many skittish portfolio managers are anxiously awaiting third-quarter numbers to make sure…

Chris Lange | Oct 5, 2015 at 8:40 AM EDT

Why Spark Therapeutics Is Up Over 50%

Spark Therapeutics made history Monday morning when it announced successful Phase 3 results in gene therapy for a genetic disease.

Chris Lange | Oct 3, 2015 at 9:15 AM EDT

5 Big FDA Decisions Expected in October

24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of October and…

Paul Ausick | Oct 2, 2015 at 1:55 PM EDT

NovoCure IPO Stumbles Out of the Gate

NovoCure entered the market sharply below the original anticipated price range and more than 15% before starting to recover.

Chris Lange | Oct 1, 2015 at 2:10 PM EDT

Pacific Biosciences Surges on New System

Pacific Biosciences of California was surging in the market on Thursday despite a sharp downturn in the health care sector…

Chris Lange | Oct 1, 2015 at 12:40 PM EDT

Surgery Partners Enters Market Well Below Expected Range

Surgery Partners entered the market on Thursday in its initial public offering priced under the expected range.

Chris Lange | Oct 1, 2015 at 8:35 AM EDT

Sarepta Makes Headway With Phase 2 Program

Sarepta Therapeutics announced additional clinical efficacy and safety data from its Phase 2b program of eteplirsen in patients with Duchenne…

Chris Lange | Sep 30, 2015 at 3:49 PM EDT

Mirna Therapeutics Sets IPO Price

ThinkstockMirna Therapeutics has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public…

Chris Lange | Sep 30, 2015 at 2:05 PM EDT

Dyax Wins Positive Opinion for European Orphan Designation

Dyax announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending…

Chris Lange | Sep 30, 2015 at 12:55 PM EDT

Civitas Readies for Secondary Offering

Selling stockholders are offering 3 million Civitas Solutions shares in a secondary offering valued up to more than $84 million.

1 … 241 242 243 244 245 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Why Mallinckrodt Shares Could Double

Aclaris Enters Market Well Below Expected Range in IPO

Why Merrill Lynch Now Favors Large Cap Leaders in Biotech

Why Sarepta Deserves Praise for Capital Raise Despite Stock Drop

Can ContraVir Sustain This Move in a Shaky Health Care Sector?

3 Biotech Stocks Loved by Portfolio Managers Now

Why Spark Therapeutics Is Up Over 50%

5 Big FDA Decisions Expected in October

NovoCure IPO Stumbles Out of the Gate

Pacific Biosciences Surges on New System

Surgery Partners Enters Market Well Below Expected Range

Sarepta Makes Headway With Phase 2 Program

Mirna Therapeutics Sets IPO Price

Dyax Wins Positive Opinion for European Orphan Designation

Civitas Readies for Secondary Offering

The Reverse Mortgage Line of Credit That Grows Untouched for 15 Years and Becomes a $700,000 Liquidity Buffer at 80

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

The Reverse Mortgage Line of Credit That Grows Untouched for 15 Years and Becomes a $700,000 Liquidity Buffer at 80

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Health and Healthcare Articles

All Health and Healthcare Articles

Why Mallinckrodt Shares Could Double

Aclaris Enters Market Well Below Expected Range in IPO

Why Merrill Lynch Now Favors Large Cap Leaders in Biotech

Why Sarepta Deserves Praise for Capital Raise Despite Stock Drop

Can ContraVir Sustain This Move in a Shaky Health Care Sector?

3 Biotech Stocks Loved by Portfolio Managers Now

Why Spark Therapeutics Is Up Over 50%

5 Big FDA Decisions Expected in October

NovoCure IPO Stumbles Out of the Gate

Pacific Biosciences Surges on New System

Surgery Partners Enters Market Well Below Expected Range

Sarepta Makes Headway With Phase 2 Program

Mirna Therapeutics Sets IPO Price

Dyax Wins Positive Opinion for European Orphan Designation

Civitas Readies for Secondary Offering

The Reverse Mortgage Line of Credit That Grows Untouched for 15 Years and Becomes a $700,000 Liquidity Buffer at 80

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how